Table 1.
Characterization of overall patient population with univariate group differences. Continuous data are presented as median (interquartile range) and tested for differences between groups by the Wilcoxon rank sum test. Categorical data are presented as counts (%) and tested for differences between groups by the chi-squared test.
| Characteristic | Survival | N | 180-day mortality | N | P-value | No ARF | N | ARF | N | P-value |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 56 (50–61) | 72 | 57 (51–62) | 26 | 0.729 | 56 (51–62) | 72 | 56 (46–62) | 22 | 0.421 |
| Male | 53 (74.7) | 71 | 18 (72.0) | 25 | 0.795 | 54 (76.1) | 71 | 15 (71.4) | 21 | 0.667 |
| Weight (kg) | 73 (65.0–83.5) | 72 | 75.5 (65.0–84.0) | 26 | 0.961 | 73 (66.0–82.5) | 72 | 74 (60.0–84.0) | 22 | 0.607 |
| Body Mass Index (kg/m2) | 25.9 (22.4–28.2) | 71 | 26 (23.0–27.3) | 26 | 0.845 | 26 (22.7–28.1) | 71 | 24.1 (22.5–27.3) | 22 | 0.292 |
| Diabetes | 16 (22.2) | 72 | 8 (30.8) | 26 | 0.385 | 17 (23.6) | 72 | 7 (31.8) | 22 | 0.44 |
| Hypertension | 22 (30.6) | 72 | 7 (26.9) | 26 | 0.728 | 21 (29.2) | 72 | 6 (27.3) | 22 | 0.864 |
| Smoking | 20 (27.8) | 72 | 6 (23.1) | 26 | 0.642 | 21 (29.2) | 72 | 5 (22.3) | 22 | 0.555 |
| ASA Class | ||||||||||
| 1 | 0 (0) | 51 | 0 (0) | 18 | 0.770 | 0 (0) | 51 | 0 (0) | 15 | 0.690 |
| 2 | 5 (9.8) | 1 (5.6) | 5 (9.8) | 1 (6.7) | ||||||
| 3 | 40 (78.4) | 14 (77.8) | 40 (78.4) | 11 (73.3) | ||||||
| 4 | 6 (11.8) | 3 (16.7) | 6 (11.8) | 3 (20.0) | ||||||
| Child-Pugh Score | ||||||||||
| A | 17 (30.9) | 7 (31.8) | 16 (28.1) | 5 (29.4) | ||||||
| B | 22 (40.0) | 8 (36.4) | 24 (42.1) | 5 (29.4) | ||||||
| C | 16 (29.1) | 55 | 7 (31.8) | 22 | 0.953 | 17 (29.8) | 57 | 7 (41.2) | 17 | 0.587 |
| MELD | 18 (11–20) | 72 | 17 (11–20) | 26 | 0.977 | 16 (10–19) | 72 | 20 (16–25) | 22 | 0.006 |
| Piggyback Technique | 30 (41.7) | 72 | 7 (28.0) | 25 | 0.226 | 29 (40.9) | 71 | 7 (31.8) | 22 | 0.448 |
| Marginal Donor | 34 (47.2) | 72 | 10 (38.5) | 26 | 0.441 | 36 (50.0) | 72 | 8 (36.4) | 22 | 0.262 |
| INR | 1.49 (1.20–1.80) | 72 | 1.56 (1.30–1.70) | 26 | 0.454 | 1.48 (1.20–1.73) | 72 | 1.61 (1.39–1.83) | 22 | 0.15 |
| Direct bilirubin (mg/dL) | 1.17 (0.48–1.97) | 68 | 0.91 (0.60–2.35) | 25 | 0.845 | 1.13 (0.48–1.79) | 70 | 1.88 (0.71–4.80) | 20 | 0.066 |
| Total bilirubin (mg/dL) | 1.5 (0.59–3.08) | 70 | 1.54 (0.80–2.64) | 26 | 0.378 | 1.5 (0.66–3.08) | 70 | 1.99 (1.06–4.10) | 22 | 0.144 |
| Albumin (g/dL) | 3.20 (2.90–3.60) | 72 | 2.90 (2.35–3.23) | 25 | 0.007 | 3.20 (2.90–3.60) | 72 | 2.80 (2.40–3.20) | 21 | 0.009 |
| Creatinine (mg/dL) | 0.90 (0.80–1.12) | 72 | 0.90 (0.70–1.50) | 26 | 0.984 | 0.90 (0.80–1.10) | 72 | 1.10 (0.70–2.10) | 22 | 0.131 |
ARF: Acute renal failure.
MELD: model for end-stage liver disease score.
INR: international normalized ratio of prothrombin time.
ASA: American Society of Anesthesiologists.